Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
fluticasone propionate controlled release (EP-104) / Eupraxia Pharma
2021-000859-39: A Phase 2 Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients with Osteoarthritis of the Knee	Not yet recruiting	2	300	Europe	EP-104IAR, Powder and solution for suspension for injection	Eupraxia Pharmaceuticals Inc., Eupraxia Pharmaceuticals Inc.	Osteoarthritis of the knee, Knee osteoarthritis, Diseases [C] - Musculoskeletal Diseases [C05]
SPRINGBOARD, NCT04120402 / 2021-000859-39: Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee	Completed	2	318	Europe, RoW	EP-104IAR 25 mg, Vehicle	Eupraxia Pharmaceuticals Inc., NBCD A/S	Osteoarthritis, Knee	05/23	06/23
RESOLVE, NCT05608681 / 2024-516689-13-00: A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).	Recruiting	1/2	117	Europe, Canada, RoW	EP-104GI, Matching vehicle control	Eupraxia Pharmaceuticals Inc., Eupraxia Pharmaceuticals Inc.	Eosinophilic Esophagitis	12/26	12/26
EP-104IAR-102, 2024-516689-13-00: A Trial to Evaluate EP 104GI in Adults with Eosinophilic Esophagitis (EoE) (RESOLVE)	Recruiting	1/2	5	Europe	TETRACOSACTIDE , EP-104GI	Eupraxia Pharmaceuticals Inc., Eupraxia Pharmaceuticals Inc.	Eosinophilic esophagitis